Practical Considerations Administration: DSIP is typically administered via subcutaneous injection, usually in the evening 30-60 minutes before bed
Individual results vary with starting weight, dose, diet, and consistency, so treat any figure as a range rather than a promise
GHK-Cu (Copper Peptide) Research Overview Last updated: February 2026 Important notice: This page is provided for educational and informational purposes only
Redness and swelling may occur, and the area may be painful for a few hours
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
